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Abstract
Introduction: In cerebrovascular disorders, special attention is paid to a hypertensive cerebrovascular crisis, which 
combines a vascular injury of the brain and hypertension. The paper studies the cerebrovascular properties of the calci-
um channel blocker of S-Amlodipine nicotinate antihypertensive agent.
Materials and methods: Tests were performed on 96 nonlinear male rats, measuring local blood flow in the cerebral 
cortex in 36 awake animals, using a laser Doppler flowmeter. Cerebral circulation was recorded in the animals when 
modeling ischemic and hemorrhagic brain injuries.
Results and discussion: S-Amlodipine nicotinate (0.1 mg/kg i/v) shows a pronounced cerebrovascular activity in the 
models of ischemic and hemorrhagic injuries of the brain. In terms of the vasodilating effect in ischemic brain injury, 
the drug is comparable to mexidol, nimodipine, picamilon, but is superior to nimodipine and picamilon in terms of 
duration of action, and in the model of hemorrhagic stroke, S-Amlodipine nicotinate is superior to nimodipine and is 
comparable to picamilon and mexidol. The analysis of the mechanism of action of the agent revealed the participation 
of GABA A-receptors in the implementation of cerebrovascular properties of the agent.
Conclusion: Significant cerebrovascular activity of S-Amlodipine nicotinate (0.1 mg/kg i/v) antihypertensive agent 
was revealed. The presence of GABAergic mechanism on cerebral blood flow in the agent action along with blockade 
of slow calcium channels ensures its high efficacy in treatment of both ischemic and hemorrhagic brain injuries.
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Introduction
Cerebrovascular diseases are among the leading causes 
of death and disability of the population of the Russian 
Federation and other countries (Benjamin et al. 2019, Sk-
vortsova et al. 2018). Currently, restoration of blood sup-
ply to the affected area of the brain for the rapid supply of 
oxygen and glucosein is a generally recognized strategy 
in the treatment of patients with ischemic cerebrovascular 
disorders. This is shown by the high efficacy of reperfu-
sion therapy which includes a combination of systemic 
thrombolysis and mechanical thrombectomy using stent 
retrievers (Lee 2017, Skvortsova et al. 2018). Vasoactive 
agents are widely used in neurological practice, such as 
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mexidol (Tanashyan et al. 2012, Voronina 2000), picami-
lon (Gusev et al. 2018, Mirzoyan et al. 2018) and a cal-
cium channel blocker nimodipine (Nishizawa et al. 2008, 
Scriabine and van den Kerckhoff 1988), which possess 
significant cerebrovascular antiischemic activity (Mir-
zoyan et al. 2018).
It is well-known that an inhibitory neurotransmitter – 
GABA – is also involved in the regulation of cerebral cir-
culation, dilating cerebral vessels as a result of interaction 
with GABA A-receptors located in the vessels (Krause et 
al.1980, Mirzoyan et al. 1970, Napoleon et al. 1987). In 
the ischemic brain injury, the balance between inhibito-
ry GABAergic and stimulating glutamatergic systems is 
disturbed in the central nervous system. In this case, an 
excess amount of glutamate is formed in the brain tissue, 
which is released and triggers a complex cascade of neu-
rotoxic processes that leads to the death of nervous tissue 
(Lai et al. 2014). To prevent this process and reduce the 
neurotoxic effect of glutamate, either a blockade of glu-
tamate receptors or activation of GABAergic neurotrans-
mission in the brain is necessary (Green et al. 2000, Liu 
et al. 2013, Schwartz-Bloom and Sah 2001, Sorokina et 
al. 2002). It is indicative that both mexidol and picamilon 
show their greatest cerebrovascular reactivity in cerebral 
ischemic injuries and this effect is eliminated or offset by 
specific blockers of GABA A-receptors (Gnezdilova et al. 
2010, Silkina et al. 2005). Thus, agents with a GABAer-
gic component in the mechanism of action in the cerebral 
ischemic injury, by activating the GABAergic system, 
contribute to the restoration of balance between inhibito-
ry and excitatory processes in the central nervous system.
In cerebrovascular disorders, special attention is paid 
to a hypertensive cerebrovascular crisis, which combines 
a vascular injury of the brain and hypertension. Such pa-
tients are prescribed complex therapy, consisting of agents 
that affect both cerebral circulation and blood pressure.
Therefore, looking for and studying new agents with 
pronounced cerebrovascular and hypotensive activity to 
treat patients with cerebrovascular diseases combined 
with hypertensive conditions, is an urgent task of modern 
pharmacology. In this aspect, the main focus of the pres-
ent study was an antihypertensive agent – S-Amlodipine 
nicotinate (Kim et al. 2008).
The aim of the study was a comparative study of the in-
fluence of S-Amlodipine nicotinate, amlodipine besylate 
on blood pressure and of the above-mentioned salts of 
amlodipine, as well as mexidole, nimodipine and picami-
lon on cerebral blood flow and blood pressure in ischemic 
and hemorrhagic injuries of the brain with the analysis of 
the mechanism of their cerebrovascular effect.
Materials and methods
The study was performed on 132 nonlinear male rats 
weighing 250–300 g, including 96 anesthetized (with 
chloral hydrate, 400 mg/kg, or urethane, 1300 mg/kg, in-
traperitoneally) and 36 awake animals. The experiments 
were carried out in compliance with the ethical rules of 
animal welfare, approved by the Ethical Committee of 
Zakusov Institute of Pharmacology.
Blood pressure was recorded in awake rats in the cau-
dal artery. Systolic blood pressure was measured with 
NIBP 200A device by BIOPAC System Inc. (small animal 
tail noninvasive blood pressure system) before adminis-
tration of the agent or distilled water and 1, 2, 4, 6 and 
24 hours after administration. Heart rate was determined 
by the number of pulses per minute on the electrocardio-
gram in the 2nd lead. Respiration rate was determined by 
the number of animal breaths per minute. Registration of 
local cerebral blood flow in the parietal cortex of rats was 
performed with an ALF-21 laser Doppler flowmeter by 
Transonic System Inc. (USA). At the same time, changes 
in the level of blood pressure in the femoral artery were 
recorded. All measurements were recorded with a pol-
ygraph by BIOPAС (USA), and the recording was per-
formed digitally on a personal computer.
To assess changes in regional cerebral blood flow in 
rats, blood flow to the brain in the internal carotid artery 
was recorded using a T106 ultrasonic volume flowme-
ter by Transonic System Inc. (USA). The sensor was in-
stalled on the common carotid artery in rats after ligation 
of its outer branch.
Global transient ischemia was induced in rats by oc-
clusion using clamps on both common carotid arteries for 
10 minutes with simultaneous reduction of blood pressure 
by bloodletting to 40–50 mm Hg. Ten minutes later, the 
clamps were removed, and the blood was reinfused. The 
substances were administered 40–45 minutes after global 
transient brain ischemia after hemodynamic parameters 
had stabilized.
Simulation of intracerebral haemorrhage was performed 
in anesthetized rats in a stereotaxic apparatus according 
to the method by A.N. Makarenko et al. (2002). With the 
help of a special device (mandren-knife), the destruction 
of brain tissue in the area of the internal capsule was car-
ried out, followed (2–3 minutes later) by the introduction 
of arterial blood which had been taken from the femoral 
artery of the animal into the injured zone. The agents were 
administered 40 minutes after all the procedures.
Statistical data processing was performed using Stа-
tistica 8.0 software package (StatSoft, USA). The data is 
presented as a median. The confidence level of p≤0.05 
was considered statistically significant.
A radioreceptor analysis of the impact of the substanc-
es on the specific binding of [3H]-SR 95531 (gabazine) 
was performed according to the modified methods in 
vitro, using membrane preparations containing GABA 
A-receptors in the frontal cortex of rats (Hawkinson et al. 
1996). Radioactivity of each sample was measured with 
a Tri-Carb 2900 TR (Perkin Elmer) scintillation counter 
with a counting efficiency of 42–45%. The results were 
processed using GraphPad Prism 5.0 software.
The study used the following substances: S-Amlodip-
ine nicotinate (by ECOCHEM-INNOVATIONS LLC to 
the order of Consortium-PIK LLC, Russia); amlodipine 
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besylate (by Shanghai Rokem International Trading Co., 
Ltd., China); nimodipine (by BayerAG, Germany); mex-
idol (service division of Zakusov Institute of Pharma-
cology, Russia); picamilon (by Pharmstandard, Russia), 
which were administered through a polyethylene catheter 
into the femoral vein of animals.
Results and discussion
Study of the effect of S-Amlodipine nicotinate and am-
lodipine besylate on the blood pressure of awake rats
The study started with examination of antihypertensive 
properties of S-Amlodipine nicotinate versus amlodipine 
besylate. The agents were studied in two doses – 5 and 10 
mg/kg with intragastric administration (per os). The study 
showed that S-Amlodipine nicotinate causes a decrease in 
blood pressure in awake rats (n=10) by an average of 40 
% of the baseline. Hypotensive effect of the agent at this 
level is maintained for 6 hours. After 24 hours, the pres-
sure level remains low and averages 26% of the baseline. 
The reference agent – amlodipine besylate at a dose of 10 
mg/kg in awake rats (n=10) – causes a decrease in blood 
pressure levels as soon as 1 hour later on average by 16%, 
i.e. it is inferior to S-Amlodipine nicotinate in efficiency 
(40%, p<0.05).
The experiments showed that distilled water had no ef-
fect on the systolic pressure of the studied animals (n=10). 
The pressure level was about 100 mm Hg throughout the 
experiment.
The study showed that S-Amlodipine nicotinate did not 
cause significant changes in either respiration rate or heart 
rate in the experimental animals throughout the experiment.
Thus, the study of the effect of S-Amlodipine nicotinate 
in comparison with that of amlodipine besylate on the level 
of blood pressure in awake rats made it possible to estab-
lish that S-Amlodipine nicotinate in awake rats significant-
ly exceeded amlodipine besylate in terms of the amplitude 
and duration of the effect (Gan’shina et al. 2014).
The influence of S-Amlodipine nicotinate, amlodipine 
besylate, mexidol, picamilon, and nimodipine on cere-
bral blood flow in global transient cerebral ischemia
Given the cerebrovascular activity of nicotinic acid, which 
is part of S-Amlodipine nicotinate, it was interesting to 
study the effect of the agent on cerebral circulation. The 
experiments showed that S-Amlodipine nicotinate at a 
dose of 0.1 mg/kg 10 minutes after intravenous adminis-
tration caused an increase in cerebral blood flow in the 
carotid artery system by an average of 64.5% (n=10). The 
effect of the agent persisted for 60 minutes or longer. Ten 
minutes after administration of the agent, the level of blood 
pressure in these experiments decreased by an average of 
32%. The hypotensive effect persisted until the end of the 
experiment. The effect of amlodipine besylate was also 
studied in regional cerebral blood flow, at a dose of 0.1 
mg/kg with intravenous administration. The experiments 
showed that amlodipine besylate caused a small statisti-
cally insignificant increase in cerebral blood flow after 10 
minutes in 7 experiments out of 10. The hypotensive effect 
of the agent persisted throughout the experiment.
The experiments showed that S-Amlodipine nicotinate 
(0.1 mg/kg, i/v) in the anesthetized rats in global tran-
sient ischemia immediately after administration caused 
an increase in local cerebral blood flow, which by the 90th 
minute was 42.5% (n=10) of the control level (Fig. 1). In 
ischemic brain damage, S-Amlodipine nicotinate causes a 
gradually developing and by the end of the experiment sig-
nificant decrease in blood pressure by an average of 6.6%.
In the study of the effect of amlodipine besylate (0.1 mg/
kg, i/v) on the local cerebral blood flow in rats in global tran-
sient ischemia, it was shown that the agent caused a small 
slowly progressing increase in the blood flow in the cerebral 
cortex of rats, which by the 40th minute after administration 
of the agent was on average 10.7% (n=10) (Fig. 1).
Then the blood flow returned to the baseline, and by 
the end of the experiment there was a slight decrease. The 
level of blood pressure under the influence of amlodipine 
besylate gradually decreased by 8.2% 10 minutes after 
its administration. The hypotensive effect of amlodipine 
besylate increased throughout the observation period and 
by the end of the experiment averaged 25.7%.
Thus, S-Amlodipine nicotinate improves blood sup-
ply to the rat brain in the condition of its ischemic lesion, 
associated with developing hypotension, and by its cere-
brovascular anti-ischemic activity it significantly exceeds 
amlodipine besylate (42.5% and 16%; p<0.05).
Mexidol, as a reference agent, in rats at a dose of 200 
mg/kg with intravenous administration after global transient 
ischemia, in contrast to intact animals, causes a gradual in-
crease in local cerebral blood flow in the cortex of animals, 
which at the 90th minute is an average of 43% (n=11) (Fig. 1).
Picamilon (50 mg/kg i/v), administered 40 min after 
global transient ischemia in anesthetized rats, also causes a 
gradual increase in local cerebral blood flow, which by the 
50th minute reaches an average of 32% (n=10) (Fig. 1). At 
Figure 1. Effect of S-Amlodipine nicotinate (Aml.nic., 0.1 
mg/kg, i/v), amlodipine besylate (Aml.bes., 0.1 mg/kg, i/v), 
nimodipine (0.03 mg/kg, i/v), mexidol (200mg/kg, i/v) and pi-
camilon (50mg/K, i/v) on the local blood flow (%) in the cere-
bral cortex of rats after global transient ischemia.
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Figure 2. Effect of S-Amlodipine nicotinate (1), picamilon (2), 
mexidol (3) and nimodipine (4) on local blood flow (%) in the 
cerebral cortex of rats 30 min (background) after hemorrhag-
ic injury. Control – changes in hemorrhagic brain injury. Note: 
* – р<0.05 between the agent and control, # – р<0.05 between 
S-Amlodipine nicotinate and picamilon with nimodipine.
similar intervals, under the influence of picamilon, there 
is a decrease in blood pressure, which by the 90th minute 
after administration of the agent is 18% of the initial level.
Nimodipine in experiments with global transient is-
chemia in animals immediately after intravenous adminis-
tration at a dose of 0.03 mg/kg causes an increase in local 
blood flow in the cerebral cortex of rats by an average of 
44.3% (n=10). However, after 10 minutes, the effect of ni-
modipine wears off, averaging 17.3%, and remains at this 
level until the end of the experiment (Fig. 1). Nimodipine 
in animals with global transient brain ischemia causes a 
decrease in blood pressure by an average of 39.6% (dur-
ing the 1st minute) and 17% (10 minutes or more).
Thus, S-Amlodipine nicotinate causes a significant in-
crease in local cerebral blood flow in rats with global tran-
sient brain ischemia, i.e. has a pronounced cerebrovascu-
lar anti-ischemic effect. The amplitude of the vasodilator 
effect of the agent is comparable to mexidol, nimodipine, 
picamilone and superior to amlodipine besylate in terms 
of the effect amplitude, and to nimodipine and picamilon 
in terms of the effect duration.
The influence of S-Amlodipine nicotinate, mexidol, pi-
camilon and nimodipine on cerebral blood flow in the 
model of brain hemorrhagic injury
The experiments showed that hemorrhagic injury to the 
internal capsule of the brain caused a significant decrease 
in the level of cerebral blood flow in the cerebral cortex 
of rats in both ipsilateral and contralateral hemispheres. 
The level of local cerebral blood flow decreased immedi-
ately after the simulation of hemorrhagic stroke, after 30 
minutes was an average of 27% of the baseline (p<0.05), 
then the blood flow continued to decrease and by the 90th 
minute was 40% (n=10). After hemorrhagic brain inju-
ry, multidirectional changes in blood pressure were ob-
served. The level of blood pressure generally reduced by 
an average of 12%. The absence of a direct link between 
changes in cerebral blood flow and blood pressure indi-
cates that the decrease of blood supply to the brain was 
due to a significant constrictor reaction of cerebral ves-
sels. The studied substances were administered 30 minu-
tes after the procedure of hemorrhagic injury.
The experiments showed that S-Amlodipine nicoti-
nate (0.1 mg/kg i/v) in the model of hemorrhagic stroke 
after a slight decrease in cerebral blood flow caused its 
increase, which by the 40–60th minutes was an average of 
36% (n=10), i.e. restored blood flow to the baseline (Fig. 
2). It should be noted that in these conditions, under the 
influence of S-Amlodipine nicotinate, a certain decrease 
in blood pressure by the 40–60th minutes after administra-
tion was followed by a slight 14%.increase.
Mexidol at a dose of 200 mg/kg when administered in-
travenously to anesthetized rats in the simulation of hem-
orrhagic stroke causes a gradual increase in local blood 
flow in the cerebral cortex of rats, which by the 60th min-
ute after administration of the agent averaged to 20 % of 
the baseline (n=10) (Fig. 2). The level of blood pressure 
reduced by the 10th minute by an average of 10 %, and 
then restored to the initial level.
Picamilon, when administered 30 minutes after hem-
orrhagic brain injury at a dose of 50 mg/kg intravenous-
ly, causes a slowly progressing increase in local cerebral 
blood flow, which by the 50th minute of observation is an 
average of 21 % (n=10) (Fig. 2). Blood pressure in these 
conditions does not undergo significant changes.
Nimodipine (0.03 mg/kg i/v), after hemorrhagic brain 
damage by the 10th minute after administration, causes a 
slight increase in local blood flow by an average of 10.3 
% (n=9) (Fig. 2). Then the blood flow gradually decreas-
es and reaches the baseline by the 60th minute. Blood 
pressure immediately after administration of the agent 
Figure 3. Effect of mexidol (1), nimodipine (2), S-Amlodipine 
nicotinate (3) and picamilon (4) on changes in local blood flow 
(%) in rat cerebral cortex in the model of hemorrhagic stroke (I) 
and after global transient ischemia (II). Note: * – р<0.05 – be-
tween ischemic and hemorrhagic brain injuries.
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decreases by 13%, which quickly recovers and does not 
undergo significant changes throughout the experiment.
Therefore, S-Amlodipine nicotinate increases blood 
flow to the brain in the model of hemorrhagic stroke. The 
amplitude of the cerebrovascular effect of the agent is su-
perior to that of nimodipine and is comparable with that 
of picamilon and mexidol.
The results of the last two sections are summarized 
in Figure 3, which shows that a statistically significant 
difference in the cerebrovascular effects of mexidol and 
nimodipine was revealed when they were studied in is-
chemic and hemorrhagic brain injuries, i.e. in hemorrhag-
ic lesion, the vasodilating activity of the agents is signifi-
cantly weakened.
A different picture is observed in the comparative study 
of S-Amlodipine nicotinate and picamilon. These drugs 
improve the blood supply to the rat brain to the same ex-
tent both in ischemic and hemorrhagic injuries (Mirzoyan 
et al. 2018).
Analysis of anti-ischemic cerebrovascular effect of S-Am-
lodipine nicotinate, mexidol, picamilon and nimodipine
Taking into account the crucial role of GABAergic me-
chanisms in the regulation of cerebral circulation, the in-
fluence of pharmacological agents on the local cerebral 
blood flow of rats subjected to global transient ische-
mia and after the preliminary introduction of a specific 
GABA A-receptor blocker – bicuculline (0.5 mg/kg; n=8) 
– was studied. The experiments showed that in these 
conditions, S-Amlodipine nicotinate did not cause sig-
nificant changes in local cerebral blood flow, whereas in 
control experiments blood flow increased by an average 
of 42.5 % (Fig. 4). The data obtained point at the GA-
BAergic mechanism of the cerebrovascular anti-ische-
mic effect of the agent.
When studying the mechanism of cerebrovascular ef-
fect of mexidol (200 mg/kg, i/v), it was shown that 10 
minutes after its administration in ischemic conditions 
and under the influence of bicuculline, local cerebral 
blood flow in most experiments decreased by an average 
of 10.2 % (control: 43 %). Blood pressure under the in-
fluence of mexidol in these conditions also reduced by an 
average of 17.3 % (Gnezdilova et al. 2010). These data 
indicate that GABA A-receptors participated in the imple-
mentation of vasodilator effect of the drug (Fig. 4).
To clarify the mechanism of the cerebrovascular ef-
fect of picamilon, its effect on local cerebral blood flow 
was studied under the influence of the GABA A-receptor 
blocker – picrotoxin (0.5 mg/kg, i/v). It turned out that 
in these conditions the agent increased cerebral blood 
flow by only 6.0 % (control: 32 %), i.e. to a much lesser 
extent than in the control (Silkina et al. 2005). Conse-
quently, the cerebrovascular effect of picamilon is me-
diated through the chlorine channel of the GABA A-re-
ceptor (Fig. 4).
Nimodipine exhibits vasodilator activity both in is-
chemic brain damage, and against the influence of the 
antagonist GABA A-receptors of bicuculline in global 
transient ischemia (n=8). Consequently, GABAergic 
mechanisms are not involved in the implementation of the 
cerebrovascular effect of nimodipine (Fig. 4).
The obtained data became the basis for a detailed 
study of the role of GABA system in the detected ef-
fects of S-Amlodipine nicotinate. In particular, the abil-
ity of S-Amlodipine nicotinate to interact directly with 
GABA A-receptors using rat brain membranes (n=6) was 
studied in a series of experiments by in vitro radioligand 
analysis. In similar conditions, amlodipine besylate, am-
lodipine (base) and nimodipine were also studied. It was 
found that S-Amlodipine nicotinate competed for specif-
ic binding sites [3H]-SR 95531 (gabazine) with IC50=18 
µm. Аmlodipine besylate (IC50=25µm) showed a close 
degree of affinity to GABA A-receptors, while amlodip-
ine (base) and nimodipine were inactive (IC50>1 mM) 
(Fig. 5). Therefore, unlike nimodipine, only salts of am-
lodipine and, to a greater extent, of S-Amlodipine nic-
otinate interact with GABA A-receptors of brain tissues 
(Kim et al. 2017).
Figure 4. The effect of S-Amlodipine nicotinate (1), mexidol (2), 
picamilon (3) and nimodipine (4) on the blood supply to the brain 
of rats in global transient ischemia (the agent) and against the 
effect of the antagonists of the GABA A-receptor (Ant.+ agent).
Figure 5. Effect of S-Amlodipine nicotinate, amlodipine 
besylate, amlodipine (base) and nimodipine on GABA A-rece-
tors in rat brain in vitro. Note: Along Y axis – the degree of 
specific ligand binding [3H]-SR 95531. Along X axis – the con-
centration of substances in mol/l.
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Conclusion
The study showed that S-Amlodipine nicotinate is supe-
rior to amlodipine besylate in efficacy and duration of the 
hypotensive effect, which corresponds to the literature 
data (Kim et al. 2008).
In terms of cerebral ischemia, S-Amlodipine nicotinate 
in its cerebrovascular effect is comparable to mexidol, ni-
modipine and picamilon, but exceeds nimodipine and pi-
camilon in terms of duration of the effect.
In hemorrhagic brain injury, S-Amlodipine nicotinate 
in its vasodilator effect is superior to nimodipine and is 
comparable to mexidol and picamilon. The presence of 
the GABAergic component in the mechanism of S-am-
lodipine action in combination with blockade of the slow 
calcium channels ensures its high efficacy in treatment of 
both ischemic and hemorrhagic brain injuries.
Therefore, it is promising to further expand the pre-
clinical study of S-Amlodipine nicotinate with a view 
to its subsequent clinical study and implementation in 
neurological practice. The ability of S-Amlodipine nic-
otinate to dilate the vessels of the brain in both ischemic 
and hemorrhagic injuries makes it worthwhile to study 
the agent in conditions where cerebrovascular diseases 
are combined with hypertension: in hypertensive cere-
bral crisis, hemorrhagic brain injuries in the period of 
angiospasm and hypertension, with neurosurgical surgi-
cal interventions, including surgical treatment of hemor-
rhagic stroke.
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